Release Date: March 31, 2022
Expiration Date: March 31, 2023

Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Join Dr. Witt as he explains how to optimize DOAC pharmacokinetics in patients with obesity. Topics include hemostasis, the impact of obesity on clot formation, and the effects of obesity on DOAC absorption, distribution, metabolism, and excretion.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurse practitioners, pharmacists and other allied healthcare professionals who provide care to patients with venous thromboembolism.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Understand the pathophysiologic mechanisms underlying the increased risk of venous thromboembolism associated with obesity
• Describe the potential impact of obesity on DOAC absorption, distribution, metabolism, and excretion

Agenda

• VTE Pathophysiology and DOAC Pharmacokinetics in Obesity  – Daniel M. Witt, PharmD, FCCP, BCPS 

Instructions for Participation and Credit

This activity is eligible for credit through March 31, 2023. After this date, this activity will expire and no further credit will be awarded.

1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Daniel M. Witt, PharmD, FCCP, BCPS
Professor and Chair
Department of Pharmacotherapy
Assistant Dean of Clinical Affairs
University of Utah College of Pharmacy
Salt Lake City, Utah

Dr. Daniel Witt received his PharmD degree from the University of Washington. He completed a clinical pharmacy residency at the University of Washington and Harborview Medical Centers, Seattle, Washington, and an advanced residency in primary care and family medicine at the University of Washington. He is Professor and Chair of the Department of Pharmacotherapy, as well as Assistant Dean for Clinical Affairs at the University of Utah College of Pharmacy, Salt Lake City. 

Dr. Witt is currently serving as a panel member for venous thromboembolism (VTE) guidelines being developed by the American Society of Hematology (ASH). He also serves on the board of directors for the Anticoagulation Forum, and is a member of the American College of Clinical Pharmacy, American Society of Health-Systems Pharmacists, and the International Society on Thrombosis and Haemostasis. He has authored/co-authored more than 90 journal articles, 11 book chapters, and given numerous lectures for continuing education programs. His research interests center on providing practical information regarding the optimal use of anticoagulation therapy to frontline practitioners and patients.

Accreditation

	CME CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
	CPE CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-22-003-H01-P. Knowledge-based CPE activity. In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program. International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Faculty Disclosures

Dr. Daniel Witt, faculty for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.

Planning Committee

Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Lillian McVey, Medical Writer, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

©2022 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.